Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. - Wikidata - wikimedia - TriplyDB

Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma.

Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma.

http://www.wikidata.org/entity/Q33501444

about

Iodine-131-meta-iodobenzylguanidine therapy for patients with high-risk neuroblastoma Stem cell transplantation for neuroblastoma Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy Feasibility of Administering High-Dose (131) I-MIBG Therapy to Children with High-Risk Neuroblastoma Without Lead-Lined Rooms.131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients Toxicity of upfront ¹³¹I-metaiodobenzylguanidine (¹³¹I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG).Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.131I MIBG therapy in neuroblastoma: mechanisms, rationale, and current status Incorporation of high-dose 131I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study Intensification of therapy using hematopoietic stem-cell support for high-risk neuroblastoma.Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma.Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131I-mIBG therapy Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults.Patient-specific dosimetry using pretherapy [¹²⁴I]m-iodobenzylguanidine ([¹²⁴I]mIBG) dynamic PET/CT imaging before [¹³¹I]mIBG targeted radionuclide therapy for neuroblastoma.A kit method for the high level synthesis of [211At]MABG.Promising therapeutic targets in neuroblastoma Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG)Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.PPARgamma in Neuroblastoma.Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study.Radiation therapy to the primary and postinduction chemotherapy MIBG-avid sites in high-risk neuroblastoma High-risk neuroblastoma: a therapy in evolution.Autologous and allogeneic cellular therapies for high-risk pediatric solid tumors.Neuroblastoma: the impact of biology and cooperation leading to personalized treatments.Radionuclide therapy of adrenal tumors.131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.Children's Oncology Group's 2013 blueprint for research: neuroblastoma.Acute changes in blood pressure in patients with neuroblastoma treated with ¹³¹I-metaiodobenzylguanidine (MIBG).A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials.Transcript Analysis for Internal Biodosimetry Using Peripheral Blood from Neuroblastoma Patients Treated with (131)I-mIBG, a Targeted Radionuclide.Treatment of high-risk neuroblastoma.Megatherapy combining I(131) metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma.Chronic neuroblastoma.Meeting the nursing challenges in treating children with 131I-MIBG.Engraftment after myeloablative doses of 131I-metaiodobenzylguanidine followed by autologous bone marrow transplantation for treatment of refractory neuroblastoma.Norepinephrine Transporter as a Target for Imaging and Therapy.Radionuclides in oncology clinical practice - review of the literature.

P2860

Q24201280-C6628ACD-8703-42D5-8203-39C65D79A43B Q24629221-E92760E3-2C4B-4D0D-BCAE-42D782446A19 Q28350866-70EFC3BE-6F37-480B-A792-7CD1F7C21F3F Q30730580-FEACCCB0-3B51-44BA-AFA5-768184E30CBC Q33330978-2FC73635-5470-4543-842B-6FA88BF06EBC Q33409568-2B40874A-616D-43AB-B0BA-42EDCE0B5259 Q33420546-58CFE03F-6D34-4EF1-9206-C95A60101A54 Q33427090-E888D017-EC63-4280-81F6-FD7AA902549D Q33428982-A16998AF-7FE4-41EC-9676-170734A15EA9 Q33652433-9622C428-A7BF-4CFA-9F43-110749BA9EAF Q33691441-4C6D2105-2B2D-4841-A12B-DB422BEE25E0 Q33788210-4FABF79D-BCDA-4DAE-950C-990E5F6C3071 Q34424834-CE709433-0D85-409B-B304-79ADCB8C3F58 Q34543646-E0926DBB-A08C-4412-9469-E245DF171925 Q35074813-5D3D8689-8B8B-4035-A42C-B57875846654 Q35109012-9C680621-3617-46F0-AACE-8CD8CD366C61 Q35828025-40CB07C6-16F6-4683-80A9-D3A6518AC19D Q36055313-ABE0FB86-E87F-4DF3-A7C2-1D310A145F43 Q36167173-06815E48-18C3-4EF7-A98B-5020CC236777 Q36353230-34F06C59-4C5B-4472-8E48-8C765F53930A Q36678476-32D60457-7354-42B4-A2B0-286B0C6DA87C Q37078231-4DAACA5E-E099-42B9-AC20-891ADAD1D44F Q37334748-08544C2E-F8BA-46BC-B67B-54038583768C Q37411975-CC4E4921-8B19-4980-8BF1-ACE366D6C84D Q37642871-EDFDD067-7D19-4CA2-8816-69A7A5D40B2B Q37716119-D43995F1-8D5D-47F1-B30B-E5CD08E8E9CE Q38014527-1132296D-850C-421A-9719-9AF712196B26 Q38020428-8D8B92E5-350F-4639-89DE-417632C42550 Q38048241-22732684-21C2-4F2F-98A2-E13BCD5A8387 Q38068818-D706EBBF-3258-4CF0-9B7D-956AC6E6C8ED Q38101306-C5FD16CA-2A7F-413E-B1C5-E7704B90B0BC Q38961012-2986D9C9-0B84-4A1C-B917-DA784C13E8B6 Q39458724-BEA0BCA9-80FA-4184-9CA2-BB7D433ED79B Q41761113-A0E4D5D1-880F-415E-93A7-D423B0DE0B5E Q43586513-2D031B36-B0EF-4F38-8F61-282DE1709EFB Q44128430-7C326E8F-08EB-4CB8-A58A-38069DAA1C43 Q44825627-6CD634A9-9C53-4AA6-B073-E17C0A3A635A Q45948464-EC754FA5-DDF0-4457-AFB0-ED89673D5D95 Q47867820-FFC6197D-5770-478F-B467-7C52B2C530FF Q47916271-154AED97-D78E-48C2-9D14-95C4252C6D56

P2860

Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma.

http://www.wikidata.org/entity/Q33501444

description

1998 nî lūn-bûn

@nan

1998 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

1998 թվականի հունվարին հրատարակված գիտական հոդված

@hy

1998年の論文

@ja

1998年論文

@yue

1998年論文

@zh-hant

1998年論文

@zh-hk

1998年論文

@zh-mo

1998年論文

@zh-tw

1998年论文

@wuu

name

Phase I dose escalation of 131 ...... t in refractory neuroblastoma.

@ast

Phase I dose escalation of 131 ...... t in refractory neuroblastoma.

@en

type

label

Phase I dose escalation of 131 ...... t in refractory neuroblastoma.

@ast

Phase I dose escalation of 131 ...... t in refractory neuroblastoma.

@en

prefLabel

Phase I dose escalation of 131 ...... t in refractory neuroblastoma.

@ast

Phase I dose escalation of 131 ...... t in refractory neuroblastoma.

@en

P1433

Q33501444-4E6C00AD-3751-460A-BC84-4BBF2E1A7AC9

P1476

Q33501444-A24EC758-72D6-4038-AC9D-219CF2F5201B

P2093

Q33501444-052D9F87-C62D-4643-9DDC-4E2554B122F0

Q33501444-0D0C26E7-1449-4089-9EA7-B530A7119438

Q33501444-23D620F6-98CA-45E6-A82E-883BAC52D243

Q33501444-40B0A889-29EC-40BF-9FF7-FEB7005C84F1

Q33501444-43DAED0C-83F8-40F2-BCD9-00F808D593E7

Q33501444-4922AED3-9A8F-4F26-9DD1-508A93C3F665

Q33501444-4CE14CD9-EDA8-4279-8EA2-11869A888B75

Q33501444-C3E58207-6279-4EC3-BA84-A70281A851B2

Q33501444-EB4FDDBC-11F8-4A04-8E55-A3E049D1A424

Q33501444-F3F74536-FEAC-401F-808B-B186500D5C5C

P304

Q33501444-933478B9-E364-4059-BADE-59C505AE2E3B

P31

Q33501444-7F8E7A97-3B65-43D8-98B5-25195E0F93E0

P356

Q33501444-E61D0CCC-ECE6-45B9-B3BC-33F34ED9DD73

P407

Q33501444-B6A4B35A-3627-4BF7-BF70-3A8827DA82B9

P433

Q33501444-81F5E6DC-F59C-4999-90D9-0A5EB6BAD314

P478

Q33501444-0DA29667-C7C0-4E6C-A8CF-4E99C75AB9EA

P577

Q33501444-1BB0E6C6-80AE-4C1A-A742-80A69D5EE30F

P698

Q33501444-A3224A97-A229-457C-AE68-F587927141E5

P921

Q33501444-3ED1823B-37C5-4C0C-B528-EF4E6F2AA421

P356

JCO.1998.16.1.229

P1433

Journal of Clinical Oncology

P1476

Phase I dose escalation of 131 ...... t in refractory neuroblastoma.

@en

P2093

A Ablin

http://www.w3.org/2001/XMLSchema#string

B Hasegawa

http://www.w3.org/2001/XMLSchema#string

C P Reynolds

http://www.w3.org/2001/XMLSchema#string

D Price

http://www.w3.org/2001/XMLSchema#string

J Huberty

http://www.w3.org/2001/XMLSchema#string

K DeSantes

http://www.w3.org/2001/XMLSchema#string

K K Matthay

http://www.w3.org/2001/XMLSchema#string

R C Seeger

http://www.w3.org/2001/XMLSchema#string

R S Hattner

http://www.w3.org/2001/XMLSchema#string

V K Weinberg

http://www.w3.org/2001/XMLSchema#string

P304

229-236

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.1998.16.1.229

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

1998-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

9440747

http://www.w3.org/2001/XMLSchema#string

P921